Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric patients deserve better, Karuna’s mission is to harness the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways that will advance the standard of care.

Biotechnology

Karuna Therapeutics

Bill Meury

Steven Paul

Tanya Glidden

Amanda Orban

Stephanie Hodges

Alicia Meli

Frank Truslow

Jackie Cohen

Gregg Pratt

Mia Kelley

Will Kane

Andrew Miller

Troy A. Ignelzi

Stephen Brannan

The Advisory Board at Karuna Therapeutics consists of distinguished Scientific Advisory Board Members who provide expert guidance on clinical development strategies, research directions, and scientific validation of novel therapies. Their role is critical in ensuring that the company’s initiatives are aligned with the latest scientific advancements and regulatory requirements, ultimately aiding in the mission to improve the lives of individuals with CNS disorders.

Advisory Board

Medical and Clinical Operations

Directors

Leadership Team

Advisory Board

About

Team members

Other teams at Karuna Therapeutics

Medical and Clinical Operations

Directors

Leadership Team